FDA 批准双靶向疗法用于头颈癌
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
FDA 批准了 subcutaneous amivantamab 和 hyaluronidase 用于治疗复发或转移性头颈鳞状细胞癌,总体响应率为 42%,显著高于现有疗法。
FDA 批准了用于头颈癌的新疗法,响应率显著高于现有疗法。
— Overall response rate was 42% in a population with limited treatment options
November 6, 2026 • 2 min read
The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma.
The approved indication is for patients whose disease has progressed on or after platinum-based chemotherapy and immunotherapy, and does not include patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma, the agency noted.
The approval was based on results from the phase Ib/II OrigAMI-4 trial involving 102 patients with recurrent or metastatic head and neck squamous cell carcinoma. The overall response rate was 42% with subcutaneous amivantamab, including a complete response in 15% of patients, with 56% of responders maintaining their response for 6 months or longer.
Currently approved therapies are linked to overall response rates of up to 20% and poor outcomes, the FDA noted.
"Today's approval represents a meaningful step forward for patients with head and neck squamous cell carcinoma, a disease where treatment options have historically been limited and outcomes remain poor," said Angelo De Claro, MD, director of the FDA's Oncology Center of Excellence. "This therapy offers patients and their physicians a new option with the potential to make a real difference in people's lives."
Amivantamab (Rybrevant) targets both EGFR and MET, two key drivers of tumor progression in head and neck cancer. In 2024, the FDA approved intravenous amivantamab plus combination chemotherapy for the first-line treatment of non-small cell lung cancer in patients whose tumors harbor EGFR exon 20 insertion mutations. Last year, the agency approved subcutaneous amivantamab and hyaluronidase for adults across all indications approved for the intravenous formulation of amivantamab.
In a press release from maker Johnson & Johnson, OrigAMI-4 investigator Barbara Burtness, MD, of the Yale Cancer Center in New Haven, Connecticut, noted that the "findings represent important progress and highlight the potential of dual EGFR- and MET-targeting with amivantamab as a distinct treatment approach in recurrent or metastatic head and neck cancer."
The prescribing information includes warnings and precautions for hypersensitivity and administration-related reactions, interstitial lung disease/pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity.
Full approval for this indication may be contingent on results from the ongoing confirmatory phase III OrigAMI-5 study, which is evaluating subcutaneous amivantamab in combination with carboplatin and pembrolizumab (Keytruda) as a first-line treatment for patients with recurrent or metastatic head and neck cancer.
来源:MedPage Today · medpagetoday.com